Clinical Trial Update: PALbociclib Endocrine Therapy Followed by Talazo Vs. Talazoz-Atezo Study [Phase 2]

View source ↗

Summary

A Phase 2 trial sponsored by Samsung Medical Center is evaluating palbociclib-based endocrine therapy followed by Talazo versus Talazoparib plus atezolizumab in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• IBRANCE (PALBOCICLIB)
• Talzenna (talazoparib)
• Tecentriq (atezolizumab)

Snippet

Sponsor: Samsung Medical Center | Conditions: Premenopausal HR+/HER2- Metastatic Breast Cancer | Phase 2 | Status: RECRUITING